TY  - JOUR
AU  - Garcia-Sanz, R
AU  - Sureda, A
AU  - de la Cruz, F
AU  - Canales, M
AU  - Gonzalez, A P
AU  - Pinana, J L
AU  - Rodriguez, A
AU  - Gutierrez, A
AU  - Domingo-Domenech, E
AU  - Sanchez-Gonzalez, B
AU  - Rodriguez, G
AU  - Lopez, J
AU  - Moreno, M
AU  - Rodriguez-Salazar, M J
AU  - Jimenez-Cabrera, S
AU  - Caballero, M D
AU  - Martinez, C
PY  - 2019
DO  - 10.1093/annonc/mdz009
UR  - http://hdl.handle.net/10668/13432
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve the results before autologous stem-cell transplantation (ASCT). This...
LA  - en
KW  - Hodgkin lymphoma
KW  - brentuximab vedotin
KW  - polychemotherapy
KW  - refractory
KW  - transplant
KW  - Administration, Intravenous
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Brentuximab Vedotin
KW  - Chemotherapy-Induced Febrile Neutropenia
KW  - Cisplatin
KW  - Cytarabine
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Etoposide
KW  - Female
KW  - Follow-Up Studies
KW  - Hematopoietic Stem Cell Transplantation
KW  - Hodgkin Disease
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Recurrence, Local
KW  - Prednisone
KW  - Progression-Free Survival
KW  - Salvage Therapy
KW  - Transplantation, Autologous
KW  - Young Adult
TI  - Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
TY  - research article
VL  - 30
ER  -